الفهرس | Only 14 pages are availabe for public view |
Abstract Abstract Aim of the study:Study of the effect of topical antiglaucoma medications with different preservatives as Purite preservative & Benzalkonium chloride on the ocular surface and dry eye . Methodology: This is cross section case-control study in which we tested the effect of topical antiglaucoma medications with different preservatives. Our study included 20 controls (group A) & 40 glaucoma patients (group B) divided into 20 patients using Alpha-agonist eyedrops containing Purite as preservative & 20 patients using B-blocker eyedrops containing Benzalkonium Chloride(BAK) as preservative. The patients were recruited from Outpatient Clinic of Ain Shams University Hospital and the controls from the patients coming to the outpatient clinic seeking correction of an error of refraction during the period from May 2016 to December 2016. Results: Our study showed that ocular surface damage in glaucoma patients is associated with preserved topical medications. There were statistically significant differences between the glaucoma-treated patients (used Alpha agonist eyedrops with Purite preservative and B blocker eyedrops with BAK as preservative) and control group in the clinical tests used to diagnose Ocular Surface Disease(OSD). In this study, Tear Break up Time(TBUT) was significantly reduced in glaucoma patients with topical medications as compared to that in controls.Also the Schirmer test values were significantly different between glaucoma-treated patients and untreated controls. Conclusion: B blocker eyedrops induce more damage on the ocular surface compared to Alpha agonist eyedrops suggesting that Purite preservatives have less dryness effect than BAK-chloride preservatives. Key words:Dry eye-Glaucoma-antiglaucoma medications-ocular surface diseasepreservatives. |